Marshall Wace
CUE icon

Marshall Wace’s Cue Biopharma CUE Stock Holding History

Marshall Wace’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-874
Closed -$58K – 3003
2022
Q3 		$58K Sell
874
-925
-51% -$79.6K ﹤0.01% 3233
2022
Q2 		$134K Buy
+1,799
New +$210K ﹤0.01% 3237
2021
Q4 		– Sell
-878
Closed -$384K – 3925
2021
Q3 		$384K Sell
878
-177
-17% -$61.7K ﹤0.01% 2534
2021
Q2 		$369K Buy
+1,055
New +$409K ﹤0.01% 2256
2021
Q1 		– Sell
-1,262
Closed -$473K – 2534
2020
Q4 		$473K Buy
+1,262
New +$504K ﹤0.01% 1478
2020
Q1 		– Sell
-3
Closed -$2K – 1689
2019
Q4 		$2K Buy
+3
New +$942 ﹤0.01% 1630

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's CUE Position: Q4 2022 in Review

Marshall Wace sold out of Cue Biopharma (CUE) in Q4 2022, closing a stake of 874 shares — an estimated $58K sold.

Marshall Wace first reported a position in CUE in Q4 2019 and held it in 6 quarters. The position peaked at $473K in Q4 2020. 61 funds tracked by Wall St. Rank hold CUE as of Q4 2022.

  • Marshall Wace reported no remaining Cue Biopharma position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 874 Cue Biopharma shares in Q4 2022, an estimated $58K.
  • Marshall Wace first reported a position in Cue Biopharma in Q4 2019 and held it in 6 quarters.
  • Marshall Wace's Cue Biopharma position peaked at $473K in Q4 2020.
  • 61 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.